National and Kapodistrian University of Athens
Μελέτη της ρύθμισης της έκφρασης των γονιδίων της ριβονουκλεάσης κ και του BCL2L12 μέσω miRNAS, στον καρκίνο του μαστού του προστάτη
Abstract
dc:descriptionBoth breast and prostate cancer are among the most common types of cancer and are the second cause of cancer-related deaths in the female and male population respectively. However the progress in understanding molecular aspects of breast and prostate carcinogenesis and the advances in clinical management of these patients denote the paradox of the above-mentioned high rates. Much of this paradox is attributed to the clinical and molecular heterogeneity of breast and prostate cancer, which renders them a collection of diseases with variable clinical behaviors, and to the inadequacy of established clinical/pathological markers to predict the outcome of most tumors and to guide optimal treatment decisions. Therefore the recognition of novel, sensitive and reliable molecular markers, capable of improving disease diagnosis, prognosis and treatment monitoring is of great importance. BCL2L12, as a member of the BCL-2 family, is an apoptosis-related gene, which is subjected to excessive alternative splicing, producing a total of 63 alternative splice variants, eighteen of which code for different isoforms of the BCL2L12 protein. Currently, the most studied isoform is BCL2L12 is.1, but still its apoptotic role remains ambiguous, since it seems that the pre-apoptotic or anti-apoptotic behavior of this protein depends on the cellular environment. Several lines of evidence support the significance of BCL2L12 in cancer from a clinical point of view as well. Human RNase κ is an endoribonuclease, coding by a gene that consists of three exons and two intervening introns. Recently, our group demonstrated that RNase κ is subjected to alternative splicing, within the first intron, producing two transcript variants, RNase κ-01 and RNase κ-02, which code for two structurally different protein isoforms. The high percentage of amino acid conservation of human RNase κ along with its expression in a wide spectrum of tissues and developmental stages, denote its significant, but yet largely obscure, biological function. Moreover, RNase κ exhibits increased or decreased expression levels in several cancer types, suggesting its possible clinical utility as molecular cancer marker. A rapidly developing scientific field in cancer-related research is the study of microRNAs (miRNAs). MiRNAs constitute a large family of small molecules that negatively regulate, at the post-transcriptional level, the expression of genes involved in key-cellular processes. Recent data describe the marked deregulation of miRNA levels in human malignancies and suggest that they might represent novel promising cancer biomarkers. The miR-96-182-183 cluster targets the BCL2L12, whereas the miR-423-5p is suggested by several algorithms to target RNase κ. These miRNAs are associated with the progression of several neoplasms. The aim of the present thesis was the expression analysis and study of BCL2L12 variants, RNase κ, the miR-96-182-183 cluster and miR-423-5p in breast and prostate tumor, as well as their clinical evaluation as biomarkers helpful for the differential diagnosis and prognosis of these patients. An additional aim was to experimentally validate that miR-423-5p targets RNase κ gene. In order to fulfill these objectives, a statistically significant sample size of breast cancer tissues and matched non-malignant breast tissues as well as of cancerous and benign prostate tissues was initially processed via homogenization. Total RNA was isolated from the abovementioned tissue specimens and was tested in terms of quality and quantity via agarose gel electrophoresis and spectrophotometric analysis, respectively. Subsequently, total RNA was reversed transcribed into cDNA. The total RNA that was used for miRNA expression analysis, was subjected to polyadenylation, prior to reverse transcription that was conducted in the presence of a modified poly(T) adapter. The expression of BCL2L12 transcript variants and RNase κ was, firstly, studied in breast and prostate tissues, via regular RT-PCR and agarose gel electrophoresis. The mRNA transcripts, as well as miRNAs expression levels, were further quantified via Real-Time PCR, using SYBR Green chemistry and the relative quantification method. Furthermore, we examined the miR-423-5p/ RNase κ interaction using bioinformatic tools for miRNA target prediction and molecular biology techniques. The clinical evaluation of the prognostic and the differential diagnostic potential of the biomolecules under study was accomplished by using extensive biostatistical analyses. More precisely, non-parametric statistical tests were used to identify any associations between the expression levels of the genes under study and the patients’ clinicopathological characteristics. ROC curve analysis was used in order to evaluate the differential diagnostic value of the examined biomolecules. Kaplan-Meier curves and univariate logistic regression analyses were used to study the effect of each factor in the disease-free survival of the breast and prostate cancer patients. The independence of the prognostic information provided by the biomolecules under study was tested via multivariate Cox logistic regression analysis.Expression analyses showed that BCL2L12 v.1 ,v.2 και v.4 are overexpressed in breast cancer tissues compared to the non-cancerous component (v.1,p < 0.001; v.2, p = 0.009; v.4, p = 0.004). Increased BCL2L12 v.4 mRNA expression was associated with markers of unfavorable prognosis namely, advanced tumor grade (p = 0.002), ER- (p = 0.015)/PR- (p < 0.001) negativity, Ki-67-positivity (p = 0.007) and high NPI score (p = 0.033). Survival analysis disclosed that BCL2L12 v.2 overexpression (HR= 0.45, p = 0.010), is a strong and independent marker of favorable prognosis for breast cancer patients. Regarding prostate tissues, it was found that BCL2L12 v.1 and v.5 are overexpressed in prostate cancer patients compared to BPH ones (v.1, p=0.016; v.5, p=0.011). BCL2L12 v.5 mRNA levels were also elevated in patients with tumors of advanced stage (pT2c and pT3a).Regarding RNase κ the statistical analysis revealed a significant downregulation of RNase κ in CaP patients compared to BPH ones (p=0.002). RNase κ overexpression was associated with decreased risk of CaP development and can discriminate between CaP and BPH independently of serum PSA levels (p=0.001). RNase κ upregulation was also associated with less advanced (P=0.018) and less aggressive (p=0.001) tumors as well as with longer progression-free survival (PFS) (p=0.003). Finally univariate bootstrap Cox regression confirmed that RNase κ was associated with favorable prognosis (HR=0.85, p=0.002). Quantitative expression analysis showed that the miR-96-182-183 cluster is significantly upregulated in breast cancer tissues compared to the non-cancerous component (miR-96, p<0.001; miR-182, p<0.001; miR-183, p<0.001), but it is downregulated in women with triple negative breast cancer (miR-96, p=0.013; miR-182, p=0.021; miR-183, p=0.04). Indeed ROC analysis disclosed that these miRNAs exhibited a significant potential to distinguish tumors characterized as triple negative from those belonging to other molecular subtypes (miR-96, AUC=0.652, p=0.013; miR-182, AUC=0.642, p=0.021; miR-183, AUC=0.620, p<0.05). Survival analysis disclosed that miR-183 overexpression is a strong and independent marker of unfavorable prognosis in breast cancer (HR= 0.13, p=0.004). In prostate cancer the miR-96-182-183 cluster is also upregulated and as ROC analysis showed these miRNAs can differentiate patients suffering from BPH and patients with CaP (miR-96, AUC= 0.611, p = 0.007; miR-182, AUC= 0.617, p = 0.004; miR-183, AUC= 0.643, p = 0.001). miR-182 and miR-183 upregulation were also associated with more advanced (miR-182: p=0.002 and miR-183: p<0.001)and more aggressive (miR-182: p=0.03 and miR-183: p=0.001)tumors, whereas miR-96 overexpression is a strong and independent marker of favorable prognosis in prostate cancer. Conversely, miR-423-5p is downregulated in breast cancer tissues (p<0.001). Moreover, increased miR-423-5p expression was associated with markers of favorable prognosis namely, initial tumor grade (p = 0.001), ER-positivity (p = 0.019), Ki-67-negativity (p = 0.035) and luminal phenotype (p=0.004). Similarly miR-423-5p is upregulated in patients suffering from BPH (p<0.001) and according to ROC analysis miR-423-5p expression levels can discriminate between prostate cancer and BPH (AUC= 0.713, p < 0.001). Finally we developed the appropriate methodologies for the experimental validation of the miR-423-5p/RNase κ interaction. By performing these methodologies we concluded to the already experimentally confirmed conclusion that miR-423-5p targets Ogt, and we provided evidence for the firtst time that miR-423-5p targets RNase κ. In conclusion, the biomolecules that were studied represent promising molecular indicators that could aid in the differential diagnosis of and provide accurate prognostic information for breast and prostate cancer patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kladi-Skandali, Athina
- Κλάδη-Σκανδάλη, Αθηνά
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47010